The company managed to do well in the earnings. The numbers were better than estimates for revenues, while the earnings were in line with what the analysts were expecting. The revenues increased 24% to $58.6 million, compared to $47 million in Q3'12. The net income (GAAP) increased 11% to $8.4 million compared to $7.59 million in Q3'12. The last one year has been good for investors as the stock has delivered excellent growth. The management improved the revenue guidance for full fiscal 2013 to around $237 million, and the forecast for net income (non-GAAP) is around $52-53 million. For Q4'13, the revenue guidance is $60.2 - $60.6 million, and net income (non-GAAP) guidance is $9.2 - $10 million. Barclays have increased their price target for the stock from $18 to $20, and Zacks upgraded it from underperform to neutral with a PT of $17.90. The consensus rating for the stock is buy, and the PT is around $20. This indicates some upside from current levels. For the first nine months of 2013, the revenue was $177.22 million and the net income was $33.78 million compared to $146.13 million and $28.85 million respectively in the corresponding period of 2012. This is an increase of 21% in revenue, and 17% in net income. The sector is buoyant as more and more companies are asserting their patent rights. Several have filed patent infringement lawsuits against much bigger companies, and companies like Marathon Patents Group (MARA) have got settlements / licensing revenues for their patents. The management guidance indicates that RPXC will post growth in top and bottom-line in 2013. The stock has reacted positively, but more trading days are required to confirm that the momentum is building up. The stock has to cross $20 decisively to get into a higher zone.